Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Farmers Insurance
Teva
McKesson
Healthtrust
Merck
UBS
Cerilliant
Citi

Generated: June 25, 2018

DrugPatentWatch Database Preview

Lantheus Medcl Company Profile

« Back to Dashboard

What is the competitive landscape for LANTHEUS MEDCL, and when can generic versions of LANTHEUS MEDCL drugs launch?

LANTHEUS MEDCL has nine approved drugs.

There are five US patents protecting LANTHEUS MEDCL drugs.

There are eighty patent family members on LANTHEUS MEDCL drugs in thirty-four countries and twelve supplementary protection certificates in eight countries.

Summary for Lantheus Medcl
International Patents:80
US Patents:5
Tradenames:9
Ingredients:8
NDAs:9

Drugs and US Patents for Lantheus Medcl

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl TECHNELITE technetium tc-99m sodium pertechnetate generator SOLUTION;INTRAVENOUS 017771-002 Feb 12, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes 9,789,210 ➤ Sign Up ➤ Sign Up
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes 8,685,441 ➤ Sign Up ➤ Sign Up
Lantheus Medcl THALLOUS CHLORIDE TL 201 thallous chloride tl-201 INJECTABLE;INJECTION 017806-001 Approved Prior to Jan 1, 1982 AP RX Yes Yes ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Lantheus Medcl

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 5,547,656 ➤ Sign Up
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 5,585,112 ➤ Sign Up
Lantheus Medcl CARDIOLITE technetium tc-99m sestamibi kit INJECTABLE;INJECTION 019785-001 Dec 21, 1990 4,988,827*PED ➤ Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 7,060,250 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Lantheus Medcl

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,017,105 Diagnostic imaging contrast agents with extended blood retention ➤ Sign Up
8,084,056 Preparation of a lipid blend and a phospholipid suspension containing the lipid blend ➤ Sign Up
7,011,815 Diagnostic imaging contrast agents with extended blood retention ➤ Sign Up
7,229,606 Diagnostic imaging contrast agents with extended blood retention ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Lantheus Medcl Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0806968/01 Switzerland ➤ Sign Up FORMER REPRESENTANTIVE: BOVARD AG PATENTANWAELTE, CH
2007003,C0806968 Lithuania ➤ Sign Up PRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REGISTRATION NO/DATE: EU/1/05/313/001, 2005 10 05 EU/1/05/313/002, 2005 10 05 EU/1/05/313/003, 2005 10 05 EU/1/05/313/004, 2005 10 05 EU/1/05/313/005, 2005 10 05 EU/1/05/313/006, 2006 10 05 EU/1/05/313/007, 2005 10 05 EU/1/05/313/008, 2005 10 05 EU/1/05/313/00 2005100
C 037/2006 Ireland ➤ Sign Up SPC 037/2006: 20070528, EXPIRES: 20201002
0736 Netherlands ➤ Sign Up PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Argus Health
Fish and Richardson
Chinese Patent Office
McKesson
Accenture
Merck
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.